Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Crosses Below 50-Day Moving Average of $0.73

Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s share price passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $0.73 and traded as low as $0.68. Atara Biotherapeutics shares last traded at $0.71, with a volume of 832,144 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, April 5th.

Atara Biotherapeutics Price Performance

The firm’s fifty day simple moving average is $0.73 and its 200 day simple moving average is $0.81. The company has a market capitalization of $85.33 million, a PE ratio of -0.27 and a beta of 0.69.

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Hong Kong Ltd lifted its stake in shares of Atara Biotherapeutics by 343.8% in the 1st quarter. Point72 Hong Kong Ltd now owns 7,234 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 5,604 shares during the period. Tower Research Capital LLC TRC grew its stake in Atara Biotherapeutics by 334.0% in the 1st quarter. Tower Research Capital LLC TRC now owns 9,041 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 6,958 shares during the period. Two Sigma Investments LP acquired a new stake in Atara Biotherapeutics in the 3rd quarter valued at $45,000. Envestnet Asset Management Inc. purchased a new stake in Atara Biotherapeutics in the 1st quarter worth $112,000. Finally, Quantbot Technologies LP acquired a new position in Atara Biotherapeutics during the second quarter worth $106,000. 70.90% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.